Want to see SE:PTRK full AI Analyst Report?
Physitrack Limited (PTRK) AI Stock Analysis
Top Page
Physitrack Limited
(Nasdaq OMX AB:PTRK)
The score is driven by improving cash generation and a supportive technical uptrend, reinforced by a generally upbeat earnings call highlighting product launches and early EMR traction. However, it is held back materially by weak financial earnings quality (very large net losses and volatile profitability) and limited valuation support due to a negative P/E and no dividend.
Physitrack Limited (PTRK) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 188.08M
- Dividend Yield
- ―
- Average Volume (3M)
- 31.69K
- Price to Earnings (P/E)
- -2.2
- Beta (1Y)
- 0.57
- Revenue Growth
- -10.30%
- EPS Growth
- -11.59%
- Country
- Sweden
- Employees
- 33
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Healthcare Information Services
Physitrack Limited Business Overview & Revenue Model
Company Description
Physitrack PLC operates globally as a digital healthcare innovator. The company delivers a proprietary cloud-based Software-as-a-Service (SaaS) platform, utilized by a diverse range of healthcare providers, from individual practitioners to large orga...
How the Company Makes Money
Publicly detailed, company-specific breakdowns of Physitrack Limited’s revenue streams (e.g., exact pricing, segment mix, major customer concentrations, partnership terms, or per-product contribution) are null. At a high level, Physitrack’s business...
Physitrack Limited Earnings Call Summary
The call was strongly positive overall. The company delivered its highest quarterly revenue, 26% growth in the core Physitrack platform, eight consecutive quarters of positive operating cash flow, improved Wellness profitability, three product launches, and strong early EMR sign-ups. These positives outweighed the year-on-year decline in adjusted EBITDA and free cash flow, the loss of a large Wellness customer, higher group costs, and the continued investment required for the U.S. expansion and EMR rollout.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects EMR paid subscriptions to start contributing from January 2027, with the wider release on the 2nd of November, Educational Modules commercialized in the fourth quarter, and the Metropolitan Safety Net system going live in Q4 at around $26,500 annual license revenue with a 5% annual increase, while the academic healthcare system is expected to go live and generate revenue in early 2027 at around $130,000 in annual revenue and $390,000 over three years; RTM adds $8 per active patient episode. Operating costs were around EUR 2.5 million in Q3 and are expected to ease slightly in Q4, with costs likely to stay around this amount over the next couple of quarters, maybe half one next year; CapEx is expected to remain flat at $0.8 million, with no further expansion on the current CapEx levels and spend hoped to tail off over the next few quarters. Management is not forecasting margins to fall from this point and expects them to expand slightly in Q4, but has no specific margin guidance for Q4 or for 2027; the medium-term adjusted EBITDA margin target remains 40%-45%, alongside accelerating organic revenue growth, positive cash flow, and the ambition to double the business in the medium term. The company is planning to spend about EUR 120,000 on buybacks this year and, subject to board approval, EUR 250,000 a year from 2027.
Physitrack Limited Financial Statement Overview
Summary
Mixed fundamentals. Cash flow is a clear strength (solidly positive operating cash flow and improved free cash flow), and leverage appears manageable, but earnings quality is the key drag: revenue is flat versus the latest annual period and profitability has deteriorated sharply with very large net losses despite positive operating-level metrics.
Income Statement
34NegativeBalance Sheet
58NeutralCash Flow
72Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Nov 2022 | Nov 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.61M | 13.77M | 16.18M | 15.18M | 12.51M | 7.81M |
| Gross Profit | 1.77M | 518.13K | 16.18M | 3.87M | 12.37M | 7.81M |
| EBITDA | 3.53M | 4.77M | -2.09M | 7.09M | 2.57M | 1.07M |
| Net Income | -7.88M | -6.92M | -6.45M | 3.20M | 92.32K | -815.03K |
Balance Sheet | ||||||
| Total Assets | 19.07M | 19.15M | 30.51M | 38.70M | 41.31M | 32.28M |
| Cash, Cash Equivalents and Short-Term Investments | 485.31K | 654.30K | 723.39K | 536.03K | 577.74K | 13.32M |
| Total Debt | 4.23M | 3.93M | 4.81M | 3.58M | 831.66K | 1,310 |
| Total Liabilities | 8.98M | 9.23M | 11.34M | 13.13M | 18.94M | 3.63M |
| Stockholders Equity | 10.09M | 9.95M | 19.17M | 25.57M | 22.37M | 23.29M |
Cash Flow | ||||||
| Free Cash Flow | 3.45M | 3.85M | -363.54K | -773.78K | -3.04M | 654.05K |
| Operating Cash Flow | 3.50M | 3.88M | 3.13M | 2.65M | 1.45M | 659.81K |
| Investing Cash Flow | -3.52M | -3.21M | -3.49M | -5.04M | -14.78M | -4.54M |
| Financing Cash Flow | -106.70K | -726.55K | 537.79K | 2.34M | 795.50K | 14.85M |
Physitrack Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PTRK, the sentiment is Positive. The current price of 11.60 is above the 20-day moving average (MA) of 11.38, above the 50-day MA of 9.71, and above the 200-day MA of 9.09, indicating a bullish trend. The MACD of 0.84 indicates Positive momentum. The RSI at 56.47 is Neutral, neither overbought nor oversold. The STOCH value of 62.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:PTRK.
Physitrack Limited Peers Comparison
Overall Rating
SE:CARE71Outperform
SE:SUS68Neutral- SE:PTRK63Neutral
SE:XMR52Neutral
SE:KONT47Neutral
SE:AINO41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:CARE | 71Outperform | SEK 700.59M | 14.12 | ― | ― | 12.86% | 18.01% |
| SE:SUS | 68Neutral | SEK 3.00B | 32.16 | ― | ― | 8.40% | 0.74% |
| SE:PTRK | 63Neutral | SEK 188.62M | -2.17 | ― | ― | -10.30% | -11.59% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| SE:XMR | 52Neutral | SEK 35.39M | -20.71 | -351.08% | ― | -13.56% | 96.77% |
| SE:KONT | 47Neutral | SEK 44.06M | -42.41 | -1.94% | ― | 0.97% | 41.35% |
| SE:AINO | 41Neutral | SEK 40.91M | -4.18 | 133.94% | ― | -11.53% | -53.21% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:PTRK | Physitrack Limited | 11.60 | -3.40 | -22.67% | |
| SE:XMR | XMReality AB | 0.03 | 0.02 | 163.64% | |
| SE:AINO | Aino Health AB | 0.20 | 0.03 | 16.96% | |
| SE:KONT | Kontigo Care AB | 1.25 | -0.57 | -31.51% | |
| SE:SUS | Surgical Science Sweden AB | 58.85 | -23.65 | -28.67% | |
| SE:CARE | Careium AB | 28.80 | 2.50 | 9.51% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026